These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

343 related items for PubMed ID: 10201468

  • 1. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes.
    Hiroyoshi M, Tateishi K, Yasunami Y, Maeshiro K, Ono J, Matsuoka Y, Ikeda S.
    Am J Gastroenterol; 1999 Apr; 94(4):976-81. PubMed ID: 10201468
    [Abstract] [Full Text] [Related]

  • 2. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ.
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [Abstract] [Full Text] [Related]

  • 3. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O, Haugaard SB, Holst JJ, Deacon CF, Iversen J, Andersen UB, Nielsen JO, Madsbad S.
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [Abstract] [Full Text] [Related]

  • 4. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection.
    Bendet N, Scapa E, Cohen O, Bloch O, Aharoni D, Ramot Y, Weiss M, Halevi A, Rapoport MJ.
    Scand J Gastroenterol; 2004 Jul; 39(7):650-6. PubMed ID: 15370686
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
    Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Holst JJ, Krarup T.
    Regul Pept; 2007 Dec 04; 144(1-3):123-30. PubMed ID: 17692937
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Diabetologia; 2002 Aug 04; 45(8):1111-9. PubMed ID: 12189441
    [Abstract] [Full Text] [Related]

  • 9. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.
    Diabet Med; 2005 Apr 04; 22(4):470-6. PubMed ID: 15787675
    [Abstract] [Full Text] [Related]

  • 10. Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes.
    Forbes S, Moonan M, Robinson S, Anyaoku V, Patterson M, Murphy KG, Ghatei MA, Bloom SR, Johnston DG.
    Clin Endocrinol (Oxf); 2005 Jan 04; 62(1):51-5. PubMed ID: 15638870
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of growth hormone on high plasma levels of glucagon-like peptide-1 (GLP-1) in hypophysectomized rats.
    Tateishi K, Kitayama N, Ishikawa H, Mitsudome A, Hirose S.
    Exp Clin Endocrinol Diabetes; 2002 Oct 04; 110(7):361-3. PubMed ID: 12397536
    [Abstract] [Full Text] [Related]

  • 13. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus.
    Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL.
    Am Surg; 2004 Jan 04; 70(1):1-4; discussion 4-5. PubMed ID: 14964537
    [Abstract] [Full Text] [Related]

  • 14. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
    Prigeon RL, Quddusi S, Paty B, D'Alessio DA.
    Am J Physiol Endocrinol Metab; 2003 Oct 04; 285(4):E701-7. PubMed ID: 12773303
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I.
    Metabolism; 2003 Jan 04; 52(1):81-6. PubMed ID: 12524666
    [Abstract] [Full Text] [Related]

  • 17. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J.
    Regul Pept; 2005 Jun 15; 128(2):149-57. PubMed ID: 15780434
    [Abstract] [Full Text] [Related]

  • 18. Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males.
    Jeibmann A, Zahedi S, Simoni M, Nieschlag E, Byrne MM.
    Eur J Clin Invest; 2005 Sep 15; 35(9):565-72. PubMed ID: 16128863
    [Abstract] [Full Text] [Related]

  • 19. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K, Egan JM.
    Am J Physiol Endocrinol Metab; 2006 Mar 15; 290(3):E550-9. PubMed ID: 16219666
    [Abstract] [Full Text] [Related]

  • 20. Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats.
    Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G, Delzenne NM.
    J Endocrinol; 2005 Jun 15; 185(3):457-65. PubMed ID: 15930172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.